Neurology 1999;52:623
© 1999 American Academy of Neurology
Brief Communications
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
D. B. Clifford, MD,
C. Yiannoutsos, PhD,
M. Glicksman, MS,
D. M. Simpson, MD,
E. J. Singer, MD,
P. J. Piliero, MD,
C. M. Marra, MD,
G. S. Francis, MD,
J. C. McArthur, MBBS,
K. L. Tyler, MD,
A. C. Tselis, MD, PhD and
N. E. Hyslop, MD
From the Department of Neurology (Dr. Clifford and M. Glicksman), Washington University School of Medicine, St. Louis, MO; Harvard School of Public Health (Dr. Yiannoutsos), Harvard Medical School, Boston, MA; the Department of Neurology (Dr. Simpson), Mt. Sinai Medical Center, New York, NY; the Department of Neurology (Dr. Singer), University of Southern California, Los Angeles, CA; the Department of Internal Medicine (Dr. Piliero), Albany Medical College, Albany, NY; the Department of Neurology (Dr. Marra), University of Washington, Seattle, WA; the Department of Neurology (Dr. Francis), Montreal Neurologic Institute, Montreal, Canada; the Department of Neurology (J.C. McArthur), Johns Hopkins University, Baltimore, MD; the Department of Neurology (Dr. Tyler), University of Colorado, Denver, CO; the Department of Neurology (Dr. Tselis), Wayne State University, Detroit, MI; and the Department of Medicine (Dr. Hyslop), Tulane University, New Orleans, LA.
Address correspondence and reprint requests to Dr. David B. Clifford, Box 8111, Neurology, 660 South Euclid, St. Louis, MO 63110; e-mail: cliffordd{at}neuro.wustl.edu
Introduction of highly active antiretroviral therapy (HAART) has been associated with many changes in the complications of human immunodeficiency virus (HIV) infection. A cohort of 25 HIV patients with progressive multifocal leukoencephalopathy (PML) treated with HAART experienced a median survival of >46 weeks. This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV.
This article has been cited by other articles:
|
|
|
|
 
M. Brickelmaier, A. Lugovskoy, R. Kartikeyan, M. M. Reviriego-Mendoza, N. Allaire, K. Simon, R. J. Frisque, and L. Gorelik
Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro
Antimicrob. Agents Chemother.,
May 1, 2009;
53(5):
1840 - 1849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tan, R. Roda, L. Ostrow, J. McArthur, and A. Nath
PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids
Neurology,
April 28, 2009;
72(17):
1458 - 1464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Yaldizli and N. Putzki
Review: Natalizumab in the treatment of multiple sclerosis
Therapeutic Advances in Neurological Disorders,
March 1, 2009;
2(2):
115 - 128.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. O. Khatri, S. Man, G. Giovannoni, A. P. Koo, J-C Lee, B. Tucky, F. Lynn, S. Jurgensen, J. Woodworth, S. Goelz, et al.
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
Neurology,
February 3, 2009;
72(5):
402 - 409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
ANSWERS
Br J Ophthalmol,
December 1, 2008;
92(12):
1695 - 1696.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Khalili, M. K. White, F. Lublin, P. Ferrante, and J. R. Berger
Reactivation of JC virus and development of PML in patients with multiple sclerosis
Neurology,
March 27, 2007;
68(13):
985 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Martinez, J. V. Mazziotti, E. D. Efron, P. Bonardo, R. Jordan, G. Sevlever, M. Martinez, S. C. Verbanaz, Z. S. Salazar, M. F. Pardal, et al.
Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder.
Neurology,
November 14, 2006;
67(9):
1692 - 1694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J R Berger
Natalizumab and progressive multifocal leucoencephalopathy
Ann Rheum Dis,
November 1, 2006;
65(suppl_3):
iii48 - iii53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Vulliemoz, F Lurati-Ruiz, F-X Borruat, J Delavelle, I J Koralnik, T Kuntzer, J Bogousslavsky, F Picard, T Landis, and R A Du Pasquier
Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.
J. Neurol. Neurosurg. Psychiatry,
September 1, 2006;
77(9):
1079 - 1082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Miller, J. R. Berger, Y. Mootoor, S. A. Avdiushko, H. Zhu, and R. J. Kryscio
High Prevalence of Multiple Human Herpesviruses in Saliva from Human Immunodeficiency Virus-Infected Persons in the Era of Highly Active Antiretroviral Therapy
J. Clin. Microbiol.,
July 1, 2006;
44(7):
2409 - 2415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Du Pasquier, M. J. Kuroda, Y. Zheng, J. Jean-Jacques, N. L. Letvin, and I. J. Koralnik
A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy
Brain,
September 1, 2004;
127(9):
1970 - 1978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Hoffmann, H-A Horst, H Albrecht, and W Schlote
Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment
J. Neurol. Neurosurg. Psychiatry,
August 1, 2003;
74(8):
1142 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
An interesting case of hemiparesis
Postgrad. Med. J.,
June 1, 2003;
79(932):
359 - 360.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Hurley, T. Ernst, K. Khalili, L. Del Valle, I. L. Simone, and K. H. Taber
Identification of HIV-Associated Progressive Multifocal Leukoencephalopathy: Magnetic Resonance Imaging and Spectroscopy
J Neuropsychiatry Clin Neurosci,
February 1, 2003;
15(1):
1 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Richardson-Burns, B. K. Kleinschmidt-DeMasters, R. L. DeBiasi, and K. L. Tyler
Progressive Multifocal Leukoencephalopathy and Apoptosis of Infected Oligodendrocytes in the Central Nervous System of Patients With and Without AIDS
Arch Neurol,
December 1, 2002;
59(12):
1930 - 1936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. White, S. Abraham, S. Singhal, H. Manji, and C. R. A. Clarke
Progressive multifocal leucoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus
Rheumatology,
July 1, 2002;
41(7):
826 - 827.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Fontoura, J Vale, C Lima, F Scaravilli, and J Guimaraes
Progressive myoclonic ataxia and JC virus encephalitis in an AIDS patient
J. Neurol. Neurosurg. Psychiatry,
May 1, 2002;
72(5):
653 - 656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Redington and K. L. Tyler
Viral Infections of the Nervous System, 2002: Update on Diagnosis and Treatment
Arch Neurol,
May 1, 2002;
59(5):
712 - 718.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Murphy, A. C. Collier, L. A. Kalish, S. F. Assmann, M. F. Para, T. P. Flanigan, P. N. Kumar, L. Mintz, F. R. Wallach, G. J. Nemo, et al.
Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease
Ann Intern Med,
July 3, 2001;
135(1):
17 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sala, J.-P. Vartanian, P. Kousignian, J.-F. Delfraissy, Y. Taoufik, S. Wain-Hobson, and J. Gasnault
Progressive multifocal leukoencephalopathy in human immunodeficiency virus type 1-infected patients: absence of correlation between JC virus neurovirulence and polymorphisms in the transcriptional control region and the major capsid protein loci
J. Gen. Virol.,
April 1, 2001;
82(4):
899 - 907.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H MANJI and R F MILLER
Progressive multifocal leucoencephalopathy: progress in the AIDS era
J. Neurol. Neurosurg. Psychiatry,
November 1, 2000;
69(5):
569 - 571.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ammassari, A. Cingolani, P. Pezzotti, A. De Luca, R. Murri, M. L. Giancola, L. M. Larocca, and A. Antinori
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy
Neurology,
October 24, 2000;
55(8):
1194 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Seijo Martinez, G. Gonzalez-Mediero, P. Santiago, A. Rodriguez de Lope, J. Diz, C. Conde, and G. S. Visvesvara
Granulomatous Amebic Encephalitis in a Patient with AIDS: Isolation of Acanthamoeba sp. Group II from Brain Tissue and Successful Treatment with Sulfadiazine and Fluconazole
J. Clin. Microbiol.,
October 1, 2000;
38(10):
3892 - 3895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maschke, O. Kastrup, S. Esser, B. Ross, U. Hengge, and A. Hufnagel
Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)
J. Neurol. Neurosurg. Psychiatry,
September 1, 2000;
69(3):
376 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Antinori, A. Ammassari, R. Luzzati, A. Castagna, R. Maserati, G. Rizzardini, A. Ridolfo, M. Fasan, E. Vaccher, G. Landonio, et al.
Role of brain biopsy in the management of focal brain lesions in HIV-infected patients
Neurology,
February 22, 2000;
54(4):
993 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Staudinger and K. Henry
Remission of HIV myelopathy after highly active antiretroviral therapy
Neurology,
January 11, 2000;
54(1):
267 - 267.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dolin
Gaining ground in progressive multifocal leukoencephalopathy
Neurology,
February 1, 1999;
52(3):
440 - 440.
[Full Text]
[PDF]
|
|
|
|
